Keros Therapeutics, Inc. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Keros Therapeutics initiated a Phase 2 clinical trial for rinvatercept in Duchenne muscular dystrophy patients in Q2 2026, a key program milestone. Q2 2026 net loss improved to $28.7M (vs. $30.7M in Q2 2025); R&D expenses fell $21.2M to $22.3M due to transition of elritercept to Takeda partner and 2025 restructuring. Cash position declined from $287.4M (Dec 31, 2025) to $257.6M (June 30, 2026); company projects runway into H1 2028.
Why this rating
Phase 2 initiation is program progress but expected; cash burn of ~$30M/quarter is 6-7% of market cap annually, sustainable for ~1.5 years. No material partnership, financing, or clinical setback.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.